ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,527 SEK | -0.16% |
|
+2.81% | +13.37% |
| Sales 2024 * | 50.77B 553B | Sales 2025 * | 54.26B 591B | Capitalization | 215B 2,344B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.74B 95.21B | Net income 2025 * | 10.24B 112B | EV / Sales 2024 * | 4.62 x |
| Net Debt 2024 * | 19.66B 214B | Net Debt 2025 * | 12.86B 140B | EV / Sales 2025 * | 4.2 x |
| P/E ratio 2024 * |
25.1
x | P/E ratio 2025 * |
21.3
x | Employees | 89,900 |
| Yield 2024 * |
2.23% | Yield 2025 * |
2.35% | Free-Float | 96.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | +0.33% | ||
| 1 week | +3.15% | ||
| Current month | +5.99% | ||
| 1 month | +10.04% | ||
| 3 months | +10.68% | ||
| 6 months | +11.60% | ||
| Current year | +13.74% |
1 week
1 481.00
1 540.00
1 month
1 387.501 540.00
Current year
1 261.001 540.00
1 year
1 261.001 616.00
3 years
863.601 616.00
5 years
700.001 616.00
10 years
440.701 616.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 1,536 | +0.42% | 27 231 |
| 24-04-22 | 1,530 | +2.34% | 306,741 |
| 24-04-19 | 1,494 | -0.17% | 230,033 |
| 24-04-18 | 1,497 | -0.40% | 250,794 |
| 24-04-17 | 1,503 | +0.70% | 371,159 |
Delayed Quote Nasdaq Stockholm, April 23, 2024 at 03:07 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
138.8
USD
Average target price
161.7
USD
Spread / Average Target
+16.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.46% | 659B | |
| +25.31% | 557B | |
| -4.86% | 359B | |
| +16.44% | 322B | |
| +8.34% | 297B | |
| +7.39% | 210B | |
| -6.91% | 200B | |
| -8.79% | 149B | |
| -5.59% | 146B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock
